<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00514397</url>
  </required_header>
  <id_info>
    <org_study_id>CCLG-CNS-2007-04</org_study_id>
    <secondary_id>CDR0000560114</secondary_id>
    <secondary_id>EU-20746</secondary_id>
    <secondary_id>EUDRACT-2007-001768-60</secondary_id>
    <nct_id>NCT00514397</nct_id>
  </id_info>
  <brief_title>Temozolomide and Radiation Therapy in Treating Young Patients With Pontine Glioma</brief_title>
  <official_title>A Phase II Multi-Centre Study of Concomitant and Prolonged Adjuvant Temozolomide With Radiotherapy in Diffuse Pontine Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Cancer and Leukaemia Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop
      the growth of tumor cells, either by killing the cells or by stopping them from dividing.
      Radiation therapy uses high-energy x-rays to kill tumor cells. Giving temozolomide together
      with radiation therapy may kill more tumor cells.

      PURPOSE: This phase II trial is studying how well giving temozolomide together with radiation
      therapy works in treating young patients with pontine glioma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To evaluate the time to death in patients with newly diagnosed diffuse pontine gliomas,
           when treated with the combination of concomitant low-dose oral temozolomide and
           radiotherapy, followed by up to 12 months of maintenance therapy with extended low-dose
           temozolomide.

        -  To assess the quality of life of patients with diffuse pontine gliomas during and after
           treatment.

      Secondary

        -  To evaluate the time to tumor progression in patients with newly diagnosed diffuse
           pontine gliomas, when treated with the combination of concomitant low-dose oral
           temozolomide and radiotherapy, followed by up to 12 months of maintenance therapy with
           extended low-dose temozolomide.

        -  To evaluate and document toxicities from the administration of temozolomide combined
           with radiotherapy and to further study any toxicities associated with the chronic
           administration of the extended low-dose temozolomide schedule in this population group.

        -  To document radiological response to the above treatment with MR imaging and, where
           available, functional imaging.

      OUTLINE: This is a multicenter study.

        -  Chemoradiotherapy: Patients receive oral temozolomide once daily for 6 weeks (7 days per
           week) with concurrent radiotherapy (5 days per week).

      Patients without evidence of disease progression proceed to maintenance therapy beginning at
      least 4 weeks after completion of radiotherapy.

        -  Maintenance therapy: Patients receive oral temozolomide daily on days 1-21. Treatment
           repeats every 4 weeks for up to 1 year in the absence of disease progression or
           unacceptable toxicity.

      Quality of life is assessed prior to chemoradiotherapy and prior to course 1 of adjuvant
      temozolomide and prior to every 3 subsequent courses of adjuvant temozolomide.

      After completion of study therapy, patients are followed every 8 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life including health status, behavior, and the subjective experience using HUI and SDQ methods</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity, steroid usage, and radiological response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events, including abnormal laboratory parameters, as assessed by CTC criteria</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>motexafin gadolinium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

        Inclusion criteria:

          -  Newly diagnosed diffuse intrinsic lesion centered in the pons on MRI

               -  No requirement for histological diagnosis

               -  Clinical history &lt; 6 months

          -  Clinical findings must include at least 1 of the 3 following signs of brainstem tumor:

               -  Cranial nerve deficit

               -  Long tract signs

               -  Ataxia

        Exclusion criteria:

          -  Focal lesions of brainstem

          -  Predominantly exophytic tumors

        PATIENT CHARACTERISTICS:

        Inclusion criteria:

          -  Karnofsky performance status (PS) or Lansky PS 60-100% (unless reason for decrease in
             status is a direct result of neurological involvement of the brainstem glioma)

          -  Life expectancy &gt; 12 weeks

          -  Absolute neutrophil count ≥ 1,000/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Hemoglobin ≥ 10 g/dL

          -  Urea and serum creatinine &lt; 1.5 times upper limit of normal (ULN)

          -  Total and direct bilirubin &lt; 1.5 times ULN

          -  AST and ALT &lt; 3 times ULN

          -  Negative pregnancy test within 7 days prior to administration of temozolomide for
             women of childbearing potential

        Exclusion criteria:

          -  Frequent vomiting and/or medical condition, that could interfere with oral medication
             intake (e.g., partial bowel obstruction)

          -  Pregnant or breast-feeding women

        PRIOR CONCURRENT THERAPY:

        Exclusion criteria:

          -  Prior chemotherapy or radiotherapy

          -  Other concurrent investigational drugs

          -  Other concurrent chemotherapy, immunotherapy, or biologic therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Bailey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sir James Spence Institute of Child Health at Royal Victoria Infirmary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Our Lady's Hospital for Sick Children Crumlin</name>
      <address>
        <city>Dublin</city>
        <zip>12</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-353-1-409-6659</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin W. English, MD</last_name>
      <phone>44-121-333-8412</phone>
      <email>martin.english@bch.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Hospital for Children</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8AE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-117-342-0205</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amos Burke, MD</last_name>
      <phone>44-1223-348-151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Glaser, MD</last_name>
      <phone>44-113-206-4984</phone>
      <email>adam.glaser@leedsth.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johann Visser, MD</last_name>
      <phone>44-116-258-5309</phone>
      <email>johannes.visser@uhl-tr.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool Children's Hospital, Alder Hey</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-151-252-5294</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-20-7380-9950</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-20-7829-7924</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M27 4HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernadette Brennan, MD</last_name>
      <phone>44-161-922-2227</phone>
      <email>bernadette.brennan@cmmc.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir James Spence Institute of Child Health at Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <state>England</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-113-206-4985</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-115-823-0620</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oxford Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>0X3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1865-234-205</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital - Sheffield</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-114-271-7366</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-2380-794-101</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-20-8661-3455</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Belfast Hospital for Sick Children</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT12 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony McCarthy, MD</last_name>
      <phone>44-289-063-3631</phone>
      <email>anthonymcarthy@royalhospital.n.i.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Aberdeen Children's Hospital</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronica Neefjes</last_name>
      <phone>44-1224-550-217</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH9 1LF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>W. Hamish Wallace, MD</last_name>
      <phone>44-131-536-0426</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G3 8SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milind D. Ronghe, MD</last_name>
      <phone>44-141-201-9309</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital for Wales</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Traunecker, MD, PhD</last_name>
      <phone>44-29-2074-2285</phone>
      <email>heidi.traunecker@cardiffandvale.wales.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Ireland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2007</study_first_submitted>
  <study_first_submitted_qc>August 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2007</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <keyword>untreated childhood brain stem glioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Motexafin gadolinium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

